[go: up one dir, main page]

SI2968443T1 - Analogi hepcidina in njihova uporaba - Google Patents

Analogi hepcidina in njihova uporaba

Info

Publication number
SI2968443T1
SI2968443T1 SI201431924T SI201431924T SI2968443T1 SI 2968443 T1 SI2968443 T1 SI 2968443T1 SI 201431924 T SI201431924 T SI 201431924T SI 201431924 T SI201431924 T SI 201431924T SI 2968443 T1 SI2968443 T1 SI 2968443T1
Authority
SI
Slovenia
Prior art keywords
hepcidin analogues
hepcidin
analogues
Prior art date
Application number
SI201431924T
Other languages
English (en)
Inventor
Mark Leslie Smythe
Gregory Thomas Bourne
Simone Vink
Brian T. Frederick
Praveen Madala
Shelton Anne Pernille Tofteng
Jacob Ulrik Fog
Original Assignee
Protagonist Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51538499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2968443(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Protagonist Therapeutics, Inc. filed Critical Protagonist Therapeutics, Inc.
Publication of SI2968443T1 publication Critical patent/SI2968443T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
SI201431924T 2013-03-15 2014-03-17 Analogi hepcidina in njihova uporaba SI2968443T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361800284P 2013-03-15 2013-03-15
US201361800048P 2013-03-15 2013-03-15
EP14763104.8A EP2968443B1 (en) 2013-03-15 2014-03-17 Hepcidin analogues and uses thereof
PCT/US2014/030352 WO2014145561A2 (en) 2013-03-15 2014-03-17 Hepcidin analogues and uses therof

Publications (1)

Publication Number Publication Date
SI2968443T1 true SI2968443T1 (sl) 2022-01-31

Family

ID=51538499

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201431924T SI2968443T1 (sl) 2013-03-15 2014-03-17 Analogi hepcidina in njihova uporaba

Country Status (20)

Country Link
US (8) US9822157B2 (sl)
EP (2) EP4091624A1 (sl)
JP (2) JP6525471B2 (sl)
KR (1) KR102236829B1 (sl)
CN (1) CN105451755B (sl)
AU (2) AU2014232954B2 (sl)
CA (1) CA2906830C (sl)
DK (1) DK2968443T3 (sl)
ES (1) ES2901704T3 (sl)
HR (1) HRP20211911T1 (sl)
HU (1) HUE057168T2 (sl)
IL (1) IL241043B (sl)
LT (1) LT2968443T (sl)
NZ (1) NZ712029A (sl)
PL (1) PL2968443T3 (sl)
PT (1) PT2968443T (sl)
RS (1) RS62633B1 (sl)
SG (2) SG11201507226YA (sl)
SI (1) SI2968443T1 (sl)
WO (1) WO2014145561A2 (sl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1199892A1 (en) 2011-12-09 2015-07-24 The Regents Of The University Of California Modified mini-hepcidin peptides and methods of using thereof
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
AU2015243990A1 (en) 2014-04-07 2016-11-10 La Jolla Pharmaceutical Company Hepcidin mimetic peptides and uses thereof
CA2949215C (en) 2014-05-16 2023-03-14 Protagonist Therapeutics, Inc. .alpha.4.beta.7 integrin thioether peptide antagonists
AU2015279571A1 (en) * 2014-06-27 2017-02-02 Protagonist Therapeutics, Inc. Hepcidin and mini-hepcidin analogues and uses therof
EP4378536A3 (en) 2014-07-17 2024-10-09 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
EP3201217A4 (en) 2014-10-01 2018-07-18 Protagonist Therapeutics Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
SG11201702553RA (en) 2014-10-01 2017-04-27 Protagonist Therapeutics Inc NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2017117411A1 (en) * 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
CN115925790A (zh) 2016-03-23 2023-04-07 领导医疗有限公司 用于合成α4β7肽拮抗剂的方法
WO2018128828A1 (en) 2016-12-23 2018-07-12 Bayer Healthcare Llc Novel hepcidin mimetics and uses thereof
EP3570873A1 (en) * 2017-01-18 2019-11-27 La Jolla Pharmaceutical Company Compositions and methods for treating iron overload
EP4092038A1 (en) 2017-09-11 2022-11-23 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
WO2020123850A1 (en) 2018-12-13 2020-06-18 Global Blood Therapeutics, Inc. Ferroportin inhibitors and methods of use
WO2020163411A1 (en) * 2019-02-08 2020-08-13 Clear Creek Bio, Inc. Compositions and methods for inhibiting inosine monophosphate dehydrogenase
US20220105121A1 (en) * 2019-02-08 2022-04-07 Clear Creek Bio, Inc. Compositions and methods for inhibiting inosine monophosphate dehydrogenase
KR20220044277A (ko) 2019-07-10 2022-04-07 프로타고니스트 테라퓨틱스, 인코포레이티드 인터루킨-23 수용체의 펩티드 억제제 및 염증성 질환을 치료하기 위한 이의 용도
JP2022546878A (ja) 2019-09-03 2022-11-09 プロタゴニスト セラピューティクス, インコーポレイテッド コンジュゲートされたヘプシジン模倣物
WO2021146441A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021146454A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
KR102521421B1 (ko) * 2020-01-22 2023-04-14 연세대학교 산학협력단 헤테로키랄 펩티드 복합체 및 이의 자가조립 중간체를 포함한 핵자기공명분광 잔류쌍극결합 측정용 조성물
US20230226074A1 (en) 2020-04-28 2023-07-20 Global Blood Therapeutics, Inc. Methods of use for pyrimidines as ferroportin inhibitors
CA3181577A1 (en) 2020-04-28 2021-11-04 Global Blood Therapeutics, Inc. Thieno pyrimidines as ferroportin inhibitors
AU2021263818A1 (en) 2020-04-28 2022-11-03 Global Blood Therapeutics, Inc. Cycloalkyl pyrimidines as ferroportin inhibitors
CN111560051B (zh) * 2020-05-26 2022-11-25 大连工业大学 一种具有促铁吸收活性的虾源九肽及其应用
US20240018189A1 (en) * 2020-07-28 2024-01-18 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
EP4247403A4 (en) 2020-11-20 2024-12-11 JANSSEN Pharmaceutica NV COMPOSITIONS OF PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR
US20250277012A1 (en) * 2021-04-01 2025-09-04 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
BR112023026381A2 (pt) * 2021-06-14 2024-03-05 Protagonist Therapeutics Inc Miméticos de hepcidina para tratamento de hemocromatose hereditária
JP2024525732A (ja) 2021-07-14 2024-07-12 ヤンセン バイオテツク,インコーポレーテツド インターロイキン-23受容体の脂質化ペプチド阻害剤
WO2023150630A2 (en) * 2022-02-02 2023-08-10 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
EP4472995A4 (en) * 2022-02-02 2025-11-19 Protagonist Therapeutics Inc Conjugated hepcidin mimetics
US12011489B2 (en) * 2022-03-30 2024-06-18 Christopher Key Compositions and methods for treating inflammatory disease
WO2025207760A1 (en) 2024-03-27 2025-10-02 Protagonist Therapeutics, Inc. Formulations of a hepcidin peptide analogue

Family Cites Families (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684620A (en) 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
US4724229A (en) 1986-09-30 1988-02-09 Smithkline Beckman Corporation Arg-arg-arg-vasopressin antagonists
JPH02306947A (ja) 1989-05-01 1990-12-20 Monsanto Co キラルβ―アミノ酸の製造方法
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
JPH06509551A (ja) 1991-04-05 1994-10-27 ジェネンテク,インコーポレイテッド Gp II↓bIII↓aに対する高い特異性を有する血小板凝集阻害剤
US5569741A (en) 1992-07-27 1996-10-29 Biomeasure, Inc. Cyclic octapeptide neuromedin B receptor antagonists
DK0644772T3 (da) 1992-11-12 2003-06-30 Sod Conseils Rech Applic Opioid-peptider
US5293050A (en) 1993-03-25 1994-03-08 International Business Machines Corporation Semiconductor quantum dot light emitting/detecting devices
AU673731B2 (en) 1993-06-03 1996-11-21 Banyu Pharmaceutical Co., Ltd. Novel endothelin antagonistic peptide
GB9516994D0 (en) 1995-08-18 1995-10-18 Iaf Biochem Int Solution synthesis of peripheral acting analgestic opioid tetrapeptides
US6037324A (en) 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US5990084A (en) 1996-04-19 1999-11-23 Novo Nordisk A/S Compounds with growth hormone releasing properties
GB9613112D0 (en) 1996-06-21 1996-08-28 Zeneca Ltd Chemical compounds
US7122623B2 (en) 1996-07-12 2006-10-17 Adherex Technologies, Inc. Compounds and methods for modulating cell adhesion
ES2283025T3 (es) 1996-08-30 2007-10-16 Novo Nordisk A/S Derivados de glp-1.1.
US5942492A (en) 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
US5993811A (en) 1997-02-03 1999-11-30 Biology Associates, Llc Method and compositions for preventing and treating the systemic inflammatory response syndrome including sepsis
JP2001509493A (ja) 1997-07-11 2001-07-24 インナーダイン, インコーポレイテッド 放射送達構造体の調製およびシール化のための方法およびシステム
US6818617B1 (en) 1997-08-15 2004-11-16 Temple University- Of The Commonwealth System Of Higher Education EC-3, an inhibitor of α4β1 and α4β7 integrins
CA2309338A1 (en) 1997-11-24 1999-06-03 Merck & Co., Inc. Cyclic amino acid derivatives as cell adhesion inhibitors
US8038984B2 (en) 1998-06-20 2011-10-18 Washington University Membrane-permeant peptide complexes for treatment of sepsis
WO2000006243A2 (en) 1998-07-28 2000-02-10 Innerdyne, Inc. Absorbable brachytherapy and chemotherapy delivery devices and methods
US20020142374A1 (en) 1998-08-17 2002-10-03 Michael Gallo Generation of modified molecules with increased serum half-lives
US6087334A (en) 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
AUPP616598A0 (en) 1998-09-25 1998-10-15 University Of Queensland, The Auxiliary for amide bond formation
AUPP616498A0 (en) 1998-09-25 1998-10-15 University Of Queensland, The Synthesis of cyclic peptides
AUPP660698A0 (en) 1998-10-21 1998-11-12 University Of Queensland, The A method of protein engineering
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
CN1344248A (zh) 1999-03-17 2002-04-10 诺沃挪第克公司 肽的酰化方法和新酰化剂
EE200100528A (et) 1999-04-12 2003-02-17 Aventis Pharma Limited Asendatud bitsükliline heteroarüülühend, seda sisaldav farmatseutiline kompositsioon ning nende raviotstarbeline kasutamine
WO2001068586A2 (en) 2000-03-14 2001-09-20 Novartis Ag α4β1 AND α4β7 INTEGRIN INHIBITORS
US20110131679A2 (en) 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
EP1349574A2 (en) 2001-01-09 2003-10-08 MERCK PATENT GmbH Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
DE10107707A1 (de) 2001-02-19 2002-08-29 Wilex Biotechnology Gmbh Antagonisten für alpha¶4¶beta¶7¶-Integrin
WO2002079235A2 (en) 2001-03-30 2002-10-10 University Of Copenhagen Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere's disease
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
AUPS039702A0 (en) 2002-02-08 2002-03-07 University Of Queensland, The Common protein surface shapes and uses therefor
US20030166138A1 (en) 2002-02-21 2003-09-04 Todd Kinsella Cyclic peptides and analogs useful to treat allergies
CN1650012A (zh) 2002-07-24 2005-08-03 英特塞尔股份公司 来自致病病毒的备选阅读框所编码的抗原
US20040176293A1 (en) 2002-12-18 2004-09-09 Wyeth Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereof
WO2004058804A1 (en) 2002-12-24 2004-07-15 Walter And Eliza Hall Institute Of Medical Research Peptides and therapeutic uses thereof
US20070166711A1 (en) 2003-04-15 2007-07-19 Samuels Mark E Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof
WO2005044839A2 (en) 2003-11-05 2005-05-19 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
US20060030053A1 (en) * 2003-12-19 2006-02-09 Applera Corporation Methods and systems for protein and peptide evidence assembly
EP1709080B1 (en) 2004-01-09 2011-03-09 Pfizer Inc. ANTIBODIES TO MAdCAM
US8536140B2 (en) 2004-03-12 2013-09-17 Mti Meta Tech Inc. Methods for treating inflammatory bowel disease
NZ551934A (en) 2004-06-24 2009-09-25 Inst Medical W & E Hall Conjugates comprising a targeting moiety and a peptide that mimics the apoptosis-inducing BH3-only proteins
NZ554331A (en) 2004-09-23 2009-04-30 Univ Melbourne Antigenic complex for the diagnosis and treatment of porphyromonas gingivalis infection
WO2006062685A2 (en) 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
US20080300180A1 (en) 2004-11-30 2008-12-04 Gastrotech Pharma A/S Growth Hormone Secretagogue Receptor 1A Ligands
ES2622467T3 (es) 2004-12-20 2017-07-06 Antibodyshop A/S Determinación de lipocalina asociada a gelatinasa de neutrófilos (NGAL) como marcador diagnóstico para trastornos renales
US20100183617A1 (en) 2005-02-23 2010-07-22 University Of Virginia Patent Foundation Compositions and methods for regulating sas1r
US7534764B2 (en) 2005-06-29 2009-05-19 The Regents Of The University Of California Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin
WO2007038619A2 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
EP2016177A2 (en) 2006-04-12 2009-01-21 Isis Pharmaceuticals, Inc. Compositions and their uses directed to hepcidin
WO2007134395A1 (en) 2006-05-22 2007-11-29 Clinical Genomics Pty Ltd Detection method
GB0610395D0 (en) 2006-05-25 2006-07-05 Ge Healthcare Ltd Novel imaging agents
AU2007260787A1 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc IL-17 and IL-23 antagonists and methods of using the same
US20080019913A1 (en) 2006-07-07 2008-01-24 University Of Arizona Office Of Technology Transfer Enkepahlin analogs with improved bioavailability
WO2008045252A2 (en) 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
US7713937B2 (en) 2006-11-10 2010-05-11 Cara Therapeutics, Inc. Synthetic peptide amides and dimeric forms thereof
US9193790B2 (en) 2006-12-07 2015-11-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of antagonists of the interaction between HIV GP120 and A4B7 integrin
US8629250B2 (en) * 2007-02-02 2014-01-14 Amgen Inc. Hepcidin, hepcidin antagonists and methods of use
JP6017754B2 (ja) 2007-02-15 2016-11-02 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation グルカゴン/glp−1受容体コアゴニスト
ATE554791T1 (de) 2007-02-23 2012-05-15 Schering Corp Gentechnisch hergestellte anti-il-23p19- antikörper
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
CA2683145C (en) 2007-04-27 2018-06-12 Katherine E. Lewis Antagonists to il-17a, il-17f, and il-23p19 and methods of use
WO2008144041A1 (en) * 2007-05-21 2008-11-27 The Ohio State University Research Foundation Hepcidins as biomarkers for impending lupus nephritis flare
US20090131317A1 (en) 2007-06-22 2009-05-21 Affymax, Inc. Compounds and peptides that bind the trail receptor
EP2288621A4 (en) 2007-07-06 2012-01-04 Valorisation Hsj Soc En Commandite IL23 RECEPTOR ANTAGONISTS AND THEIR USE
CN101358201A (zh) 2007-07-31 2009-02-04 钱忠明 重组人铁调素腺病毒、其制备方法及应用
CN101307085B (zh) 2007-08-01 2012-06-13 香港理工大学深圳研究院 抑制铁调素调节蛋白的siRNA、重组慢病毒及其应用
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
GR1006896B (el) * 2007-08-24 2010-07-20 Ελληνικο Ινστιτουτο Παστερ, Μεθοδος παραγωγης μιας πεπτιδικης ορμονης
WO2009039185A1 (en) 2007-09-17 2009-03-26 The Trustees Of Columbia University In The City Of New York Uses of immunologically modified scaffold for tissue prevascularization and cell transplantation
WO2009045536A2 (en) 2007-10-05 2009-04-09 The University Of North Carolina At Chapel Hill Receptor targeted oligonucleotides
JP2012507723A (ja) 2008-11-03 2012-03-29 シェーリング コーポレイション 炎症性腸疾患生物マーカーおよび関連治療方法
AU2009322260B2 (en) * 2008-12-05 2013-09-12 The Regents Of The University Of California Mini-hepcidin peptides and methods of using thereof
DE102009007381A1 (de) 2009-01-29 2010-08-05 Amp-Therapeutics Gmbh & Co. Kg Antibiotische Peptide
US8999935B2 (en) 2009-02-11 2015-04-07 New York University Treatment of osteoporosis in peri- and post-menopausal women with hepcidin
JP5669728B2 (ja) 2009-04-08 2015-02-12 武田薬品工業株式会社 ニューロメジンu誘導体
TWI578992B (zh) * 2009-04-30 2017-04-21 諾克森製藥股份有限公司 與鐵調節激素(hepcidin)結合之核酸類
US20110142889A1 (en) 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
CA3008993A1 (en) 2010-01-25 2011-07-28 Cornell University Aromatic-cationic peptides and uses of same
US10416172B2 (en) 2010-03-31 2019-09-17 Medical Diagnostic Laboratories, Llc Recombinant soluble truncated IL-23 receptor (IL-23R) capable of inhibiting IL-23R-mediated cell signaling
JP2011231085A (ja) 2010-04-30 2011-11-17 Osaka Prefecture Univ 環状ペプチド
WO2011149942A2 (en) 2010-05-24 2011-12-01 Children's Medical Center Corporation Compositions and methods for plasma peptide analysis
IT1406051B1 (it) 2010-08-05 2014-02-06 D M G Italia S R L Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo.
ES2919136T3 (es) 2010-08-11 2022-07-22 Ironwood Pharmaceuticals Inc Formulaciones estables de linaclotida
EP2444101A1 (en) 2010-10-21 2012-04-25 Universitätsklinikum Freiburg Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis
US9243034B2 (en) 2011-01-27 2016-01-26 Ramot At Tel-Aviv University Ltd. Glycogen synthase kinase-3 inhibitors
US8946150B2 (en) 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US20150118315A1 (en) 2011-06-14 2015-04-30 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
US9169292B2 (en) 2011-06-14 2015-10-27 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US9605027B2 (en) 2011-06-14 2017-03-28 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
HK1199892A1 (en) 2011-12-09 2015-07-24 The Regents Of The University Of California Modified mini-hepcidin peptides and methods of using thereof
CA2873511A1 (en) 2012-05-17 2013-11-21 Ra Pharmaceuticals, Inc. Peptide and peptidomimetic inhibitors
WO2013177432A1 (en) 2012-05-23 2013-11-28 The University Of Chicago Methods of treating obesity
US9024044B2 (en) 2012-06-14 2015-05-05 Ajinomoto Co., Inc. Heteroarylcarboxylic acid ester derivative
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
CN105378159A (zh) 2013-02-15 2016-03-02 Srx心脏有限责任公司 调节血清低密度脂蛋白(LDL)水平的前蛋白转化酶枯草杆菌蛋白酶/Kexin 9 型(PCSK9)变构结合配体
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
US20140294902A1 (en) 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide antagonists
US20140294901A1 (en) 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide dimer antagonists
RU2732440C2 (ru) 2013-06-24 2020-09-16 Кэнбас Ко., Лтд. Пептиды и пептидомиметики для комбинированного применения и лечения в субпопуляциях пациентов с раковыми заболеваниями
CA2916492A1 (en) 2013-06-27 2014-12-31 Stealth Biotherapeutics Corp Peptide therapeutics and methods for using same
AU2014331812B2 (en) 2013-10-09 2019-01-17 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
WO2015112700A1 (en) 2014-01-22 2015-07-30 Wisconsin Alumni Research Foundation Alpha/beta-peptide mimics of z-domain peptides
AU2015243990A1 (en) 2014-04-07 2016-11-10 La Jolla Pharmaceutical Company Hepcidin mimetic peptides and uses thereof
CA2949215C (en) 2014-05-16 2023-03-14 Protagonist Therapeutics, Inc. .alpha.4.beta.7 integrin thioether peptide antagonists
WO2015183963A2 (en) 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including redox-active parabenzoquinones and uses thereof
AU2015279571A1 (en) 2014-06-27 2017-02-02 Protagonist Therapeutics, Inc. Hepcidin and mini-hepcidin analogues and uses therof
WO2016004093A2 (en) 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof
EP4378536A3 (en) 2014-07-17 2024-10-09 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
EP3201217A4 (en) 2014-10-01 2018-07-18 Protagonist Therapeutics Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
SG11201702553RA (en) 2014-10-01 2017-04-27 Protagonist Therapeutics Inc NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
US20170362292A1 (en) 2014-12-29 2017-12-21 The Regents Of The University Of California S-Alkylated Hepcidin Peptides and Methods of Making and Using Thereof
US20160199437A1 (en) 2015-01-08 2016-07-14 D. Travis Wilson Therapeutic compositions including iron chelators and uses thereof
WO2016115168A1 (en) 2015-01-12 2016-07-21 Synthorx, Inc. Incorporation of unnatural nucleotides and methods thereof
US20160228491A1 (en) 2015-02-09 2016-08-11 Stealth Biotherapeutics Corp Therapeutic compositions including phenazine-3-one and phenothiazine-3-one derivatives and uses thereof
WO2016195663A1 (en) 2015-06-02 2016-12-08 Stealth Peptides International, Inc. Therapeutic compositions including bpm 31510, variants and analogues thereof, and uses thereof
WO2016200364A1 (en) 2015-06-08 2016-12-15 Stealth Peptides International, Inc. THERAPEUTIC COMPOSITIONS INCLUDING SkQ COMPOUNDS AND USES THEREOF
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
BR112018000691A2 (pt) 2015-07-15 2018-09-18 Protagonist Therapeutics Inc inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias
EP3364967A2 (en) 2015-10-23 2018-08-29 Vifor (International) AG Ferroportin inhibitors
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
CN115925790A (zh) 2016-03-23 2023-04-07 领导医疗有限公司 用于合成α4β7肽拮抗剂的方法
WO2018022917A1 (en) 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Disulfide-rich peptide libraries and methods of use thereof
WO2018022937A1 (en) 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
WO2018048944A1 (en) 2016-09-06 2018-03-15 La Jolla Pharmceutical Company Methods of treating iron overload
US20200064357A1 (en) 2016-11-09 2020-02-27 Protagonist Therapeutics, Inc. Methods for determining and monitoring gastrointestinal inflammation
AU2017371472B2 (en) 2016-12-06 2024-08-08 Universiteit Van Amsterdam Multicyclic peptides and methods for their preparation
WO2018128828A1 (en) 2016-12-23 2018-07-12 Bayer Healthcare Llc Novel hepcidin mimetics and uses thereof
CA3049889A1 (en) 2017-01-18 2018-07-26 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
EP4092038A1 (en) 2017-09-11 2022-11-23 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
US12171764B2 (en) 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
JOP20190150A1 (ar) 2018-06-21 2019-12-21 Merck Sharp & Dohme مركبات مناهضة لـ pcsk9
TW202019948A (zh) 2018-07-12 2020-06-01 美商領導醫療有限公司 介白素-23受體之肽抑制劑及其治療發炎疾病之用途
CN113631569A (zh) 2019-03-28 2021-11-09 领导医疗有限公司 用于合成β-高氨基酸的方法
WO2021007433A1 (en) 2019-07-10 2021-01-14 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
KR20220044277A (ko) 2019-07-10 2022-04-07 프로타고니스트 테라퓨틱스, 인코포레이티드 인터루킨-23 수용체의 펩티드 억제제 및 염증성 질환을 치료하기 위한 이의 용도
JP2022546878A (ja) 2019-09-03 2022-11-09 プロタゴニスト セラピューティクス, インコーポレイテッド コンジュゲートされたヘプシジン模倣物
CA3166637A1 (en) 2020-01-10 2021-07-15 Protagonist Therapeutics, Inc. Methods for treating inflammatory bowel diseases with .alpha.4.beta.7 integrin antagonists
WO2021146454A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021146441A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021146458A1 (en) 2020-01-15 2021-07-22 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US20240018189A1 (en) 2020-07-28 2024-01-18 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
EP4247403A4 (en) 2020-11-20 2024-12-11 JANSSEN Pharmaceutica NV COMPOSITIONS OF PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR
CA3214153A1 (en) 2021-04-01 2022-10-06 Gregory Thomas Bourne Conjugated hepcidin mimetics
WO2022212698A1 (en) 2021-04-01 2022-10-06 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
US20250277012A1 (en) 2021-04-01 2025-09-04 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
BR112023026381A2 (pt) 2021-06-14 2024-03-05 Protagonist Therapeutics Inc Miméticos de hepcidina para tratamento de hemocromatose hereditária
UY39858A (es) 2021-07-14 2023-02-28 Janssen Biotech Inc Inhibidores peptídicos bicíclicos del receptor de interleucina-23
MX2024000762A (es) 2021-07-14 2024-04-18 Janssen Biotech Inc Inhibidores peptidicos del receptor de interleucina-23.
JP2024525732A (ja) 2021-07-14 2024-07-12 ヤンセン バイオテツク,インコーポレーテツド インターロイキン-23受容体の脂質化ペプチド阻害剤
US20250179196A1 (en) 2021-07-30 2025-06-05 Janssen Biotech, Inc. Materials and methods of making or using il-23r binding proteins
WO2023150630A2 (en) 2022-02-02 2023-08-10 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
EP4472995A4 (en) 2022-02-02 2025-11-19 Protagonist Therapeutics Inc Conjugated hepcidin mimetics
EP4536683A1 (en) 2022-06-07 2025-04-16 Protagonist Therapeutics, Inc. Hepcidin mimetics for treatment of sickle cell disease
WO2024011188A1 (en) 2022-07-07 2024-01-11 Protagonist Therapeutics, Inc. Combination therapy for treatment of iron overload diseases

Also Published As

Publication number Publication date
LT2968443T (lt) 2021-12-10
KR102236829B1 (ko) 2021-04-07
AU2014232954B2 (en) 2018-08-09
CN105451755B (zh) 2020-10-13
US20180100004A1 (en) 2018-04-12
IL241043B (en) 2020-04-30
US20240174726A1 (en) 2024-05-30
US10501515B2 (en) 2019-12-10
US20180086811A1 (en) 2018-03-29
EP2968443A2 (en) 2016-01-20
CA2906830C (en) 2021-07-06
US9822157B2 (en) 2017-11-21
US20220348626A1 (en) 2022-11-03
WO2014145561A2 (en) 2014-09-18
CN105451755A (zh) 2016-03-30
JP6722227B2 (ja) 2020-07-15
EP2968443A4 (en) 2016-10-26
HRP20211911T1 (hr) 2022-03-18
SG11201507226YA (en) 2015-10-29
CA2906830A1 (en) 2014-09-18
AU2018260800A1 (en) 2018-11-22
US20250340608A1 (en) 2025-11-06
US10442846B2 (en) 2019-10-15
KR20160005332A (ko) 2016-01-14
PL2968443T3 (pl) 2022-02-07
US12269856B2 (en) 2025-04-08
DK2968443T3 (da) 2021-12-06
US20190185535A1 (en) 2019-06-20
AU2014232954A1 (en) 2015-10-01
IL241043A0 (en) 2015-11-30
AU2018260800B2 (en) 2020-04-09
SG10201707622XA (en) 2017-11-29
HUE057168T2 (hu) 2022-04-28
RS62633B1 (sr) 2021-12-31
US20160222076A1 (en) 2016-08-04
JP2018123169A (ja) 2018-08-09
WO2014145561A3 (en) 2015-02-12
JP2016521257A (ja) 2016-07-21
US11807674B2 (en) 2023-11-07
ES2901704T3 (es) 2022-03-23
EP4091624A1 (en) 2022-11-23
PT2968443T (pt) 2021-12-28
NZ712029A (en) 2020-02-28
US20190185536A1 (en) 2019-06-20
US10030061B2 (en) 2018-07-24
NZ751741A (en) 2021-08-27
JP6525471B2 (ja) 2019-06-05
EP2968443B1 (en) 2021-09-29
HK1220112A1 (zh) 2017-04-28

Similar Documents

Publication Publication Date Title
IL276106A (en) Garp-binding proteins and their uses
IL274355B (en) Aza-pyridone compounds and their uses
HUE057168T2 (hu) A hepcidin analógjai és ezek alkalmazása
GB2535911B (en) Strigolactone formulations and uses thereof
ZA201508896B (en) Anti-c10orf54 antibodies and uses thereof
IL246390A0 (en) Analogues of cortistatin, their syntheses and uses
SG11201601211TA (en) Anti-prlr antibodies and uses thereof
HUE051018T2 (hu) IL-33-ellenes antitestek és alkalmazásaik
GB201323008D0 (en) Compounds and uses thereof
GB201305277D0 (en) Novel combination and use
IL240248A0 (en) Met-binding substances and their uses
IL244214A0 (en) Thienopiperidine derivative and its use
GB201315751D0 (en) Analogues
GB201307233D0 (en) Compounds and uses thereof
IL244751A0 (en) Cyclic thianouracil-carboxamides and their use
GB201320992D0 (en) Complex and uses thereof
ZA201601880B (en) Hetero-transglycosylase and uses thereof
GB201305297D0 (en) Novel agents and uses thereof
GB201301393D0 (en) Kiddibidet and pottibidet
GB201304166D0 (en) CelebQuiff and Instant Quiff
GB201323005D0 (en) Compounds and uses thereof
GB201301640D0 (en) Methods and peptides